Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects - Two prospective, multicentre, open-label, parallel-group volunteer studies

被引:40
作者
Abel, Samantha [1 ]
Allan, Richard [2 ]
Gandelman, Kuan [2 ]
Tomaszewskil, Konrad [1 ]
Webb, David J. [3 ]
Wood, Nolan D. [1 ]
机构
[1] Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, New York, NY USA
[3] Univ Edinburgh, Clin Pharmacol Unit, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
关键词
D O I
10.2165/00044011-200828070-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and objectives: Since little is known regarding the pharmacokinetics of voriconazole in renally impaired patients, two prospective, open-label, parallel-group volunteer studies were conducted to estimate the effect of renal impairment on the pharmacokinetics of oral voriconazole and intravenous voriconazole solubilized with sulphobutylether-beta-cyclodextrin (SBECD), respectively. Methods: In study A, male subjects with no (n = 6), mild (n = 6), moderate (n = 6) or severe (n = 6) renal impairment received one 200 mg dose of oral voriconazole. Voriconazole plasma levels were periodically assessed until 48 hours post-dose. In study 13, male subjects with no (n = 6) or moderate (n = 7) renal impairment received multiple doses of intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily [day 1] then 3 mg/kg twice daily [days 2-6] followed by a final dose of 3 mg/kg on the morning of day 7) at an infusion rate of 3 mg/kg/h. Voriconazole plasma levels were periodically assessed until 36 hours following the final dose. Pharmacokinetics were determined by non-compartmental methods. Results: The pharmacokinetics of voriconazole were unaffected in subjects with any degree of renal impairment in both studies. In study B, clearance of SBECD was proportional to creatinine clearance (r(2) = 0.857). Although two subjects had >30% increase in serum creatinine from baseline, these changes did not correlate with SBECD trough levels (r(2) = 0.053). The majority of subjects with moderate renal insufficiency were able to tolerate 7 days of intravenous voriconazole solubilized with SBECD. Conclusion: These data suggest that renal impairment does not affect the pharmacokinetics of voriconazole. Furthermore, in subjects with moderate renal impairment, there is a strong linear correlation between SBECD clearance and creatinine clearance, and elevated SBECD levels do not necessarily correlate with increased serum creatinine levels (an indicator of worsening renal function).
引用
收藏
页码:409 / 420
页数:12
相关论文
共 25 条
[1]   Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients [J].
Alvarez-Lerma, F ;
Nicolás-Arfelis, JM ;
Rodriguez-Borregan, JC ;
Díaz-Regañón, J ;
Sa-Borges, M ;
García-López, F ;
Allepuz-Palau, A .
JOURNAL OF CHEMOTHERAPY, 2005, 17 (04) :417-427
[2]   Voriconazole: A second-generation triazole [J].
Chandrasekar, PH ;
Manavathu, E .
DRUGS OF TODAY, 2001, 37 (02) :135-148
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus [J].
Cuenca-Estrella, M ;
Rodríguez-Tudela, JL ;
Mellado, E ;
Martínez-Suárez, JV ;
Monzón, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :531-533
[5]  
*CYDEX INC, CAPT BROCH
[6]   Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].
Desta, Z ;
Zhao, XJ ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958
[7]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[8]   Fluorescence determination of sulphobutylether-β-cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formation [J].
Gage, R ;
Venn, RF ;
Bayliss, MAJ ;
Edgington, AM ;
Roffey, SJ ;
Sorrell, B .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 22 (05) :773-780
[9]  
*GUID IND, 1998, PHARM PAT IMPA REN F
[10]   Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status [J].
Ikeda, Y ;
Umemura, K ;
Kondo, K ;
Sekiguchi, K ;
Nakashima, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :587-588